688578.SH
艾力斯
SSE · Healthcare · Biotechnology · CN
CNY 112.19
−3.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.7B | 5.2B | 3.6B | 2.0B | 791.0M |
| Cost of Revenue | 209.4M | 164.6M | 143.5M | 77.9M | 31.7M |
| Gross Profit | 5.5B | 5.0B | 3.4B | 1.9B | 759.3M |
| Operating Expenses | |||||
| R&D Expense | 435.3M | 413.4M | 314.5M | 313.1M | 191.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 146.2M | 166.9M | 164.6M | 131.5M | 92.4M |
| Selling & Marketing Expense | 2.2B | 2.1B | 1.4B | 920.5M | 431.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.8B | 2.7B | 1.9B | 1.3B | 683.8M |
| Cost and Expenses | 3.1B | 2.8B | 2.0B | 1.4B | 715.5M |
| Operating Income (EBIT) | 2.9B | 2.6B | 1.6B | 657.7M | 127.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 2.8B | 2.5B | 1.6B | 656.2M | 126.0M |
| Income Tax Expense | 396.0M | 355.8M | 188.7M | 12.0M | (4.5M) |
| Bottom Line | |||||
| Net Income | 2.4B | 2.2B | 1.4B | 644.2M | 130.5M |
| Earnings from Cont. Ops | 2.4B | 2.2B | 1.4B | 644.2M | 130.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.4B | 2.2B | 1.4B | 644.2M | 130.5M |
| Per Share | |||||
| Basic EPS | CN¥5.36 | CN¥4.86 | CN¥3.18 | CN¥1.43 | CN¥0.29 |
| Diluted EPS | CN¥5.36 | CN¥4.86 | CN¥3.18 | CN¥1.43 | CN¥0.29 |
| Revenue Per Share | CN¥12.58 | CN¥11.52 | CN¥7.91 | CN¥4.48 | CN¥1.76 |
| Shares | |||||
| Basic Shares Outstanding | 451.1M | 450.4M | 449.6M | 450.5M | 450.1M |
| Diluted Shares Outstanding | 451.1M | 450.4M | 449.6M | 450.5M | 450.1M |
| Profitability Metrics | |||||
| EBITDA | — | 2.6B | 1.7B | 695.4M | 149.7M |
| D&A | — | 41.6M | 37.5M | 37.7M | 21.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026